ICIs, including antibodies targeting programmed cell death 1 (PD1) and programmed cell death ligand 1 (PD‐L1), have demonstrated effectiveness against diverse cancers, such as melanoma, non‐small‐cell lung cancer, and renal cancer.6 This evidence concerns the gene CD274 and renal carcinoma.